2017 American Transplant Congress

April 29-May 3, 2017 in Chicago, IL

View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Detection of Right Ventricular Dilation and Dysfunction by Transthoracic Echocardiography Predicts Renal Transplant Outcomes.

F. Tinney Jr,¹ S. Lazar,² A. Naik,² M. Samaniego-Picota,² N. Bhave.²
Detection of Shared and Distinct Gene Expression Signatures in Tissue and Urine During Acute Rejection of Kidney Grafts.

K. Keslar,¹ A. Zmijewska,² J. Chen,² K. Newell,³ P. Heeger,⁴ R. Mannon,² R. Fairchild.¹
Detection of Specific B Cell Memory to the Perlecan LG3 Antigen in the Normal Immune Repertoire.

L. Padet,^1,2,3 M. Dieude,^1,2 B. Yang,^1,2,3 J. Turgeon,^1,2 H. Cardinal,^1,2 M.-J. Hebert.^1,2,3
Determinants of Severe Interstitial Fibrosis in Kidney Allografts: Major Impact of Circulating Donor-Specific Anti-HLA Antibodies.

C. Gosset, D. Viglietti, M. Rabant, E. Pillebout, J. Taupin, D. Glotz, C. Legendre, J. Duong Van-Huyen, A. Loupy, C. Lefaucheur.
Determinants of Successful Use of Sirolimus in Renal Transplantation.

M. Naik,¹ W. Gwinner,² W. Arns,³ E. Basic,¹⁰ K. Budde,¹ F. Diekmann,⁴ M. Fischereder,⁵ J. Goßmann,⁶ K. Heller,⁷ N. Heyne,⁸ J.-S. Jürgensen,¹ C. Morath,⁹ U. Riester.¹⁰
Development and Validation of an FLF-Transplant Score to Predict Mortality of Patients with Fulminant Liver Failure.

Z. Guo, B. Chen, X. He, G. Chen.
Development and Validation of PART (Pharmacotherapy Assessment in Renal Transplant Patients) Criteria to Assess Drug Related Problems in Outpatient Renal Transplant Population.

L. El Raichani,¹ Q. Du,¹ A. Mathieu,¹ S. Almassy,¹ L. Lalonde,¹ N. Boudreau,¹ E. Gélinas-Lemay,¹ D. Berbiche,³ H. Cardinal.²
Development of an Anti-HLA Antibody-Producing Humanized Mouse Model.

S. Yanagawa, H. Tahara, H. Ohdan.
Development of an Automatic Regulated Normothermic Kidney Preservation Device for Long-Term Organ Perfusion.

A. Weissenbacher,¹ O. Boubriak,² L. Lo Faro,¹ R. Ploeg,¹ J. Hunter,¹ D. Voyce,³ N. Mikov,³ A. Cook,³ C. Coussios,² P. Friend.¹
Development of De Novo Donor Specific Antibodies (dnDSAs) Not the Presence of Pre-Transplant Donor Specific Antibodies (Pre-DSAs) Increase Rejection Risk in Crossmatch Negative Kidney Transplant Recipients.

H. Khamash, L. Archambault, M. Buras, H. Kosiorek, M. Pando, K. Reddy, B. Kaplan, R. Heilman.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z